An expert panel of the EU drug regulator, the European Medicines Agency (EMA), on Friday declined to endorse Kisunla ...
Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...
After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...
The European Union's drugs regulator on Friday rejected Eli Lilly's Alzheimer's drug, saying the risk of serious brain ...
Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and ...
Eli Lilly's direct-to-consumer platform LillyDirect has been expanded to include in-person and telehealth services for people ...
Eli Lilly is expanding care offerings on its direct-to-consumer (DTC) platform LillyDirect, now offering connections to ...
The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback